Moreover, using CD27 to distinguish between memory (CD27+) and naïve (CD27−) B cells in humans, the proportion of naïve CD3−CD27−IL-10+ B cells was significantly lower in RRMS patients during relapse than those in remission. This evidence concerns the gene CD27 and relapsing-remitting multiple sclerosis.